Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma
| Autor: | Kazuya Takamochi, Takeshi Matsunaga, Shunki Hirayama, Shiaki Oh, Takuo Hayashi, Aritoshi Hattori, Kenji Suzuki |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Pulmonary and Respiratory Medicine medicine.medical_specialty Lung Neoplasms Adenocarcinoma Gastroenterology Disease-Free Survival Ground-glass opacity Stage IA Lung Adenocarcinoma Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Overall survival Humans Neoplasm Invasiveness Stage (cooking) Survival analysis Aged Neoplasm Staging Proportional Hazards Models Retrospective Studies Aged 80 and over Lung business.industry Proportional hazards model Middle Aged medicine.disease Tumor Burden Survival Rate 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Female medicine.symptom business |
| Zdroj: | Journal of Thoracic Oncology. 14:265-275 |
| ISSN: | 1556-0864 |
| DOI: | 10.1016/j.jtho.2018.09.026 |
| Popis: | Introduction We evaluated differences in the clinicopathologic characteristics and prognosis based on the presence of ground glass opacity (GGO) components in small-sized lung adenocarcinoma. Methods We retrospectively investigated 634 lung adenocarcinomas classed as c-stage IA in the eighth edition TNM classification. Staging was defined according to the solid component size measured by thin-section computed tomography. All tumors were grouped into either a GGO or solid group, based on the presence of a GGO component. Results Of the cases, 215 (34%) were classed as c-stage IA1 (T1mi: 88, T1a-GGO: 102, T1a-solid: 25), 255 (40%) as c-stage IA2 (T1b-GGO: 122, T1b-solid: 133), and 164 (26%) as c-stage IA3 (T1c-GGO: 44, T1c-solid: 120). Among the 546 c-stage IA cases excluding the T1mi lesions, Cox regression analysis revealed that presence of GGO was an independently significant prognosticator (p = 0.024). The result was validated in 494 c-stage IA lung adenocarcinomas with a nonpredominant GGO component, showing the presence of GGO as a significant prognosticator (p = 0.048). When we evaluated the prognostic impact of GGO presence in each clinical stage, the 5-year overall survival (OS) was significantly different between the GGO and solid groups (IA1: 97.8% versus 86.6%, p = 0.026; IA2: 89.3% versus 75.2%, p = 0.007; IA3: 88.5% versus 62.3%, p = 0.003). Furthermore, the 5-year overall survival b was distinct in parallel similar pathologic findings when comparing a lepidic versus an invasive component (IA1: 97.9% versus 85.6%, p = 0.031; IA2: 86.1% versus 69.4%, p = 0.007; IA3: 77.5% versus 55.8%, p Conclusions Clinicopathologic and oncologic outcomes were disparate based on the presence of a GGO component in the eighth edition TNM classification of c-stage IA lung adenocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|